NO20031521L - Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme - Google Patents

Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme

Info

Publication number
NO20031521L
NO20031521L NO20031521A NO20031521A NO20031521L NO 20031521 L NO20031521 L NO 20031521L NO 20031521 A NO20031521 A NO 20031521A NO 20031521 A NO20031521 A NO 20031521A NO 20031521 L NO20031521 L NO 20031521L
Authority
NO
Norway
Prior art keywords
association
sibutramine
obesity
treatment
receptor antagonist
Prior art date
Application number
NO20031521A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031521D0 (no
Inventor
Odile Piot-Grosjean
Philippe Picaut
Francois Petitet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8854974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20031521(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20031521D0 publication Critical patent/NO20031521D0/no
Publication of NO20031521L publication Critical patent/NO20031521L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20031521A 2000-10-04 2003-04-03 Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme NO20031521L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012646A FR2814678B1 (fr) 2000-10-04 2000-10-04 Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
PCT/FR2001/003022 WO2002028346A2 (fr) 2000-10-04 2001-10-01 Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite

Publications (2)

Publication Number Publication Date
NO20031521D0 NO20031521D0 (no) 2003-04-03
NO20031521L true NO20031521L (no) 2003-04-24

Family

ID=8854974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031521A NO20031521L (no) 2000-10-04 2003-04-03 Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme

Country Status (29)

Country Link
EP (1) EP1328269B2 (zh)
JP (1) JP4221221B2 (zh)
KR (1) KR20030036885A (zh)
CN (1) CN100409845C (zh)
AT (1) ATE267595T1 (zh)
AU (2) AU9393601A (zh)
BG (1) BG107739A (zh)
BR (1) BR0114410A (zh)
CA (1) CA2424934A1 (zh)
DE (1) DE60103556T3 (zh)
DK (1) DK1328269T5 (zh)
EA (1) EA005924B1 (zh)
EE (1) EE200300121A (zh)
ES (1) ES2217191T5 (zh)
FR (1) FR2814678B1 (zh)
HR (1) HRP20030249A2 (zh)
HU (1) HUP0302044A3 (zh)
IL (1) IL155236A0 (zh)
MX (1) MXPA03002845A (zh)
NO (1) NO20031521L (zh)
NZ (1) NZ524904A (zh)
PL (1) PL362833A1 (zh)
PT (1) PT1328269E (zh)
SI (1) SI1328269T2 (zh)
SK (1) SK4032003A3 (zh)
TR (1) TR200401264T4 (zh)
WO (1) WO2002028346A2 (zh)
YU (1) YU26103A (zh)
ZA (1) ZA200303015B (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
CA2479618A1 (en) 2002-03-26 2003-10-09 William K. Hagmann Spirocyclic amides as cannabinoid receptor modulators
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
WO2004013120A1 (en) 2002-07-29 2004-02-12 F. Hoffmann-La Roche Ag Novel benzodioxoles
DE60330392D1 (de) 2003-01-02 2010-01-14 Hoffmann La Roche Cb 1 rezeptor inversagonisten
DE60322114D1 (de) 2003-01-02 2008-08-21 Hoffmann La Roche Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7485732B2 (en) 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
CN100368407C (zh) 2003-06-20 2008-02-13 霍夫曼-拉罗奇有限公司 作为cb1受体反激动剂的2-酰氨基苯并噻唑
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
CA2537535A1 (en) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Novel medical use of selective cb1-receptor antagonists
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
WO2005049615A1 (en) * 2003-11-21 2005-06-02 Pfizer Products Inc. Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
KR100773650B1 (ko) 2003-12-08 2007-11-05 에프. 호프만-라 로슈 아게 신규한 싸이아졸 유도체
JP4436369B2 (ja) 2004-01-28 2010-03-24 エフ．ホフマン−ラ ロシュ アーゲー スピロ−ベンゾジオキソール類およびそれらのｃｂ１アンタゴニストとしての使用
ES2324720T3 (es) 2004-05-10 2009-08-13 F. Hoffmann-La Roche Ag Pirrol o imidazol amidas para tratar la obesidad.
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
FR2876689B1 (fr) * 2004-10-14 2008-02-22 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
RU2007119315A (ru) 2004-10-25 2008-11-27 Зольвай Фармасьютиклз Гмбх (De) Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
RU2394027C2 (ru) 2004-10-27 2010-07-10 Ф. Хоффманн-Ля Рош Аг Новые индольные или бензимидазольные производные
EP1812418B1 (en) 2004-11-09 2010-10-27 F. Hoffmann-La Roche AG Dibenzosuberone derivatives
ATE435207T1 (de) 2005-04-06 2009-07-15 Hoffmann La Roche Pyridin-3-carbonsäureamidderivate als cb1-inverse agonisten
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2007102999A2 (en) * 2006-02-21 2007-09-13 Ampla Pharmaceuticals Inc. Cb1 antagonists and inverse agonists
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd NEW POLYMORPHIC FROM RIMONABANT
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
BRPI0718515A2 (pt) * 2006-09-25 2013-11-19 Boehringer Ingelheim Int Compostos que modulam o receptor cb2
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
SI2234966T1 (sl) * 2007-12-18 2014-01-31 Sanofi Derivati azetidinov, njihova priprava in njihova terapevtska uporaba
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
BRPI0902481B8 (pt) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes composição farmacêutica compreendendo hemopressina e seu uso.
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61928B1 (en) † 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
JPH04360167A (ja) * 1991-06-06 1992-12-14 Mitsubishi Kasei Corp 近接帯電装置
FR2713225B1 (fr) † 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
JPH07209959A (ja) * 1994-01-24 1995-08-11 Ricoh Co Ltd 帯電装置
US5596106A (en) † 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
CA2269660A1 (en) * 1996-10-31 1998-05-07 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
FR2758723B1 (fr) † 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US6207005B1 (en) * 1997-07-29 2001-03-27 Silicon Genesis Corporation Cluster tool apparatus using plasma immersion ion implantation
EP0920864A1 (en) † 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
KR100652994B1 (ko) † 1998-09-11 2006-11-30 아방티 파르마 소시에테 아노님 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation

Also Published As

Publication number Publication date
JP2004512279A (ja) 2004-04-22
HUP0302044A2 (hu) 2003-11-28
FR2814678B1 (fr) 2002-12-20
DE60103556T2 (de) 2005-06-30
CN1473040A (zh) 2004-02-04
BG107739A (bg) 2004-01-30
EP1328269B2 (fr) 2008-07-30
YU26103A (sh) 2006-08-17
DK1328269T3 (da) 2004-09-20
HUP0302044A3 (en) 2005-05-30
JP4221221B2 (ja) 2009-02-12
SK4032003A3 (en) 2003-09-11
HRP20030249A2 (en) 2005-02-28
MXPA03002845A (es) 2004-09-10
ZA200303015B (en) 2004-02-26
SI1328269T2 (sl) 2008-12-31
BR0114410A (pt) 2004-02-17
EE200300121A (et) 2005-04-15
ES2217191T3 (es) 2004-11-01
ATE267595T1 (de) 2004-06-15
WO2002028346A3 (fr) 2002-08-29
CN100409845C (zh) 2008-08-13
FR2814678A1 (fr) 2002-04-05
DK1328269T4 (da) 2008-11-24
EA200300441A1 (ru) 2003-08-28
EP1328269B1 (fr) 2004-05-26
NZ524904A (en) 2004-11-26
DE60103556D1 (de) 2004-07-01
ES2217191T5 (es) 2009-02-16
WO2002028346A2 (fr) 2002-04-11
AU9393601A (en) 2002-04-15
EP1328269A2 (fr) 2003-07-23
KR20030036885A (ko) 2003-05-09
IL155236A0 (en) 2003-11-23
PL362833A1 (en) 2004-11-02
EA005924B1 (ru) 2005-08-25
NO20031521D0 (no) 2003-04-03
SI1328269T1 (en) 2004-10-31
AU2001293936B2 (en) 2007-01-25
TR200401264T4 (tr) 2004-07-21
DE60103556T3 (de) 2009-04-09
PT1328269E (pt) 2004-08-31
DK1328269T5 (da) 2009-03-16
CA2424934A1 (fr) 2002-04-11

Similar Documents

Publication Publication Date Title
NO20031521L (no) Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme
IL139080A0 (en) Btx inhibitors and methods for their indentification and use
IL158168A0 (en) 5-membered, nitrogen-containing heterocyclic compounds and pharmaceutical compositions containing the same
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
NO333265B3 (no) Substituerte dihydrokinazoliner, fremgangsmåte for fremstilling derav, anvendelse av en slik forbindelse samt medikament inneholdende denne.
DE60007095T2 (de) Calanolide zur hemmung von btk
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
MY137620A (en) Therapeutic treatment
DE69917230D1 (de) Kombinationspräparat, das selektive nmda nr2b-antagonisten und cox-2 inhibitoren enthält
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
NO971997D0 (no) Bruk av immunmodulerende midler
AP2004003190A0 (en) Broaspectrum substituted benzisoxazole sulfonamideHIV protease inhibitors.
WO2001004354A3 (en) Use of ras inhibitors of inhibiting muscle atrophy
NO20001751L (no) Nye forbindelser til bruk som neuroprotektive midler
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
RS47804A (en) 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
MXPA04001878A (es) Composiciones medicinales que comprenden antagonista del receptor de angiotensina ii.
ATE414540T1 (de) Impfstoffe gegen allergien
NO20040471L (no) 5,6,6a,1 1b-tetrahydro-7-oksa-5-azabenzo[c]fluoren-6-karboksylsyrederivater som NMDA-antagonister
GB0228706D0 (en) Novel therapeutic target
SI1668027T1 (sl) Ciklični peptidi delujoči kot antagonisti urotenzina ii
ATE388239T1 (de) Cgt1 als antifungales target
NO20011246L (no) Fastlåsningsanordning og nedföringsinnretning for denne, samt system for fastlåsningsanordningen og nedföringsinnretningen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application